Keeping Track: US FDA Expands Indications For Roche Tecentriq, Lucentis, Approves Second Infliximab Biosimilar

 
• By Bridget Silverman

The latest drug development news and highlights from our FDA Performance Tracker.

Keeping Track Feature image

More from Approvals

More from Product Reviews